Skip to main content
SCI logo

SCI — Investor Relations & Filings

Ticker · 4119 ISIN · TW0004119003 TW Manufacturing
Open in API
Filings indexed 1,697 across all filing types
Latest filing 2020-10-09 Regulatory Filings
Country TW Taiwan
Listing TW 4119

About SCI

www.sci-pharmtech.com.tw

SCI Pharmtech, Inc. specializes in the research, development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and specialty chemicals. Established in 1987 and originally founded by the Swiss Siegfried Group, the company provides high-quality chemical solutions and custom manufacturing services to leading global pharmaceutical corporations across Europe, North America, and Japan. Its core operations encompass advanced chemical synthesis, process optimization, and large-scale production within GMP-compliant facilities. With a robust R&D infrastructure including specialized laboratories and pilot plants, the company delivers technical excellence in complex chemical processing. SCI Pharmtech maintains a strong focus on quality assurance and international regulatory compliance, positioning itself as a reliable partner for the global healthcare and life sciences sectors.

Recent filings

Filing Released Lang Actions
109年9月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (旭富) reporting on the status of fund loans and endorsement guarantees for the current and previous month, with amounts all zero. It contains tabular data but no detailed financial statements or analysis. The content is typical of a regulatory announcement providing compliance information rather than a full financial report or management discussion. The document length is short (601 characters), and it does not indicate it is an announcement of a report publication. It fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement about financial guarantees and loans without substantive financial data or report content.
2020-10-09 Chinese
109年9月營業收入
Regulatory Filings Classification · 90% confidence The document is a revenue summary report for a company named 旭富 for the period 民國109年09月 (September 2020). It contains monthly and cumulative net operating revenue figures with comparisons to the previous year. The document is short (774 characters) and primarily provides financial summary data without detailed financial statements or analysis. It does not appear to be a full financial report like an Annual Report (10-K) or Interim Report (IR). It also does not fit into categories like Earnings Release (ER) because it lacks key highlights or narrative commentary. The document is more of a regulatory or public disclosure of financial data, typical of a Regulatory Filing (RNS) in the context of Taiwanese public company disclosures. Therefore, the best classification is Regulatory Filings (RNS).
2020-10-09 Chinese
109年08月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by insiders and related parties of the company 旭富製藥科技股份有限公司, including directors, independent directors, general managers, and other executives. It lists the number of shares held, pledged shares, and related ratios. The document is focused on insider shareholdings and does not contain financial statements, earnings data, or management discussion. It is not a report of a meeting, nor an announcement of voting results or dividends. It is a disclosure of insider shareholdings, which corresponds to the category of Director's Dealing (DIRS), as it reports personal share transactions or holdings by company directors and executives. The document length is 3152 characters, which is consistent with a detailed insider shareholding report rather than a full financial report or announcement. Therefore, the most appropriate classification is DIRS.
2020-09-15 Chinese
109年08月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document contains detailed tables listing shareholdings of insiders, including directors, managers, and their related parties. It shows changes in shareholdings, stock types, and related notes. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of it being a full financial report, earnings release, or management discussion. The document is not a brief announcement but a detailed disclosure of insider shareholdings. This matches the definition of Director's Dealing (DIRS), which reports personal share transactions by company directors and executives (insider trades).
2020-09-15 Chinese
109年8月營業收入
Regulatory Filings Classification · 90% confidence The document is a revenue summary report for a company named 旭富 for the period 民國109年08月 (August 2020). It contains monthly and cumulative net operating revenue figures with comparisons to the previous year. The document is short (773 characters) and primarily provides financial summary data without detailed financial statements or analysis. It does not appear to be a full financial report like an Annual Report (10-K) or Interim Report (IR). It also does not fit categories like Earnings Release (ER) because it lacks key highlights or narrative commentary. The document is a regulatory disclosure of financial data, typical of a general regulatory announcement. Therefore, it best fits the Regulatory Filings (RNS) category as a general financial data disclosure without the depth of a formal report.
2020-09-09 Chinese
109年8月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company (旭富) reporting on the status of fund loans and endorsement guarantees for the current and previous month, with amounts all zero. It contains no detailed financial statements, no management discussion, no audit information, and no regulatory certifications. The content is a straightforward regulatory disclosure of financial guarantees and loans, typical of a regulatory filing or compliance announcement. The document length is very short (601 characters), and it does not present a full report or detailed financial data. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory disclosures that do not fit other specific categories.
2020-09-09 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.